Tactile Systems Technology vs Viemed Healthcare
TCMD and VMD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TCMD and VMD compare
Tactile Systems Technology is the larger company, worth 1.4 times as much as Viemed Healthcare ($522M against $368M).
On earnings, Tactile Systems Technology is cheaper: it trades at 21.3× trailing earnings, against 26.9× for Viemed Healthcare.
Viemed Healthcare grew revenue faster over the last twelve months (25.2% versus 17.2% for Tactile Systems Technology).
Tactile Systems Technology keeps more of each dollar of sales as profit, with a net margin of 7.1% compared with 4.8% at Viemed Healthcare.
Tactile Systems Technology scores higher on the StockData Score (18 against 17 for Viemed Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TCMD | VMD |
|---|---|---|
| Size and price | ||
| Market cap | $522M | $368M |
| Share price | $23.04 | $9.67 |
| Change, 1 year | 51.8% | 47.9% |
| Change, 5 years | −39.3% | 59.0% |
| Beta (5Y) | 1.37 | 0.57 |
| Employees | 1,086 | 1,382 |
| StockData Score | ||
| Total score | 18 (better) | 17 |
| Valuation score | 5 (better) | 4 |
| Growth score | 3 | 5 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 21.3× (better) | 26.9× |
| P/S | 1.5× | 1.2× (better) |
| P/B | 2.3× (better) | 2.6× |
| EV/EBITDA | 10.8× | 9.5× (better) |
| P/FCF | 19.5× | 12.6× (better) |
| PEG | – | 0.83 |
| FCF yield | 5.1% | 7.9% (better) |
| Fair value | $25.86 | $10.78 |
| Margin of safety | 10.9% (better) | 10.3% |
| Growth | ||
| Revenue growth (TTM) | 17.2% | 25.2% (better) |
| Revenue growth, 5Y average | 12.0% | 15.5% (better) |
| Net income growth (TTM) | 64.5% (better) | 3.7% |
| EPS growth (TTM) | 74.2% (better) | 5.9% |
| EPS growth, 5Y average | – | −13.9% |
| Profitability | ||
| Gross margin | 76.8% (better) | 57.5% |
| Operating margin | 10.0% (better) | 7.5% |
| Net margin | 7.1% (better) | 4.8% |
| FCF margin | 7.7% | 9.7% (better) |
| Return on equity | 11.9% (better) | 10.2% |
| Return on invested capital | 16.1% (better) | 12.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.05 (better) |
| Net debt / EBITDA | – | −0.09 |
| Interest coverage | 140× | – |
| Current ratio | 4.12 (better) | 1.13 |
| Altman Z-score | 8.09 (better) | 6.42 |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 1.2% | 5.0% (better) |
| Shareholder yield | 1.2% | 5.0% (better) |
| Ownership | ||
| Held by institutions | 96.7% | 71.3% |
| Held by insiders | 4.4% | 15.4% |
| Insider net buying, 12 months | −$2.0M | −$1.6M (better) |
| Short interest, % of float | 13.2% | 4.9% |
Go deeper
- TCMD stock overview
- TCMD income statement
- TCMD valuation and score
- VMD stock overview
- VMD income statement
- VMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.